Increased Lung Expression of Anti-Angiogenic Factors in Down Syndrome: Potential Role in Abnormal Lung Vascular Growth and the Risk for Pulmonary Hypertension

@article{Galambos2016IncreasedLE,
  title={Increased Lung Expression of Anti-Angiogenic Factors in Down Syndrome: Potential Role in Abnormal Lung Vascular Growth and the Risk for Pulmonary Hypertension},
  author={C. Galambos and Angela D Minic and D. Bush and Dominique L. Nguyen and B. Dodson and G. Seedorf and S. Abman},
  journal={PLoS ONE},
  year={2016},
  volume={11}
}
  • C. Galambos, Angela D Minic, +4 authors S. Abman
  • Published 2016
  • Biology, Medicine
  • PLoS ONE
  • Background and Aims Infants with Down syndrome (DS) or Trisomy 21, are at high risk for developing pulmonary arterial hypertension (PAH), but mechanisms that increase susceptibility are poorly understood. Laboratory studies have shown that early disruption of angiogenesis during development impairs vascular and alveolar growth and causes PAH. Human chromosome 21 encodes known anti-angiogenic factors, including collagen18a1 (endostatin, ES), ß-amyloid peptide (BAP) and Down Syndrome Critical… CONTINUE READING
    24 Citations
    Pulmonary hypertension in children with Down syndrome.
    Angiogenic profile identifies pulmonary hypertension in children with Down syndrome
    • 2
    Impaired Lung Development and Neonatal Lung Diseases: A Never-Ending (Vascular) Story.
    • 3
    • Highly Influenced
    What Causes Pulmonary Arterial Hypertension in Down Syndrome With Congenital Heart Disease?
    • 2
    • PDF

    References

    SHOWING 1-10 OF 44 REFERENCES
    Clinical characteristics of pulmonary arterial hypertension associated with Down syndrome
    • T. Saji
    • Medicine
    • Pediatrics international : official journal of the Japan Pediatric Society
    • 2014
    • 31
    Down Syndrome Candidate Region 1 Isoform 1 Mediates Angiogenesis through the Calcineurin-NFAT Pathway
    • 65
    • PDF
    Role of Endogenous Angiogenesis Inhibitors in Down Syndrome
    • 39
    Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease.
    • S. Abman
    • Medicine
    • Advances in experimental medicine and biology
    • 2010
    • 82
    Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure.
    • 311
    • PDF
    Down syndrome suppression of tumor growth and the role of the calcineurin inhibitor DSCR1
    • 302
    Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.
    • 55
    • PDF
    Risk of Vascular Anomalies With Down Syndrome
    • 56
    Inhibition of angiogenesis decreases alveolarization in the developing rat lung.
    • 537
    • PDF